NONE
The present invention relates to medically implanted biocompatible power modules. More particularly, the present invention relates to integrated modules incorporating a power source (e.g. battery), a power management circuit (hereinafter “PMC”), and a magnetically inductive coupling system (hereinafter “MICS”) for transcutaneous charging and remote communication. The present invention also relates to homing devices for medically implanted apparatus.
The use of implanted medical devices is becoming increasingly important in the treatment of diseases and disabilities. Such devices include, but are not limited to, implantable cardiac defibrillators (see e.g., U.S. Pat. No. 5,817,130 to Cox et al., U.S. Pat. Nos. 6,427,083 and 6,418,342 both to Owen, et al.), cardiac pacemakers (see e.g., U.S. Pat. No. 6,421,564 to Yerich, et al. and U.S. Pat. No. 5,411,537 to Munshi et al., hereinafter the '537 patent), cardiac assist pumps (see e.g, U.S. Pat. Nos. 6,387,037 and 6,299,575 both to Bolling, U.S. Pat. Nos. 6,336,939 and 6,346,120 both to Yamazaki, Tevaearai et al., Performance of a New Implantable Cardiac Assist Centrifugal Pump, International Society for Artificial Organs, February 2000 <http://www.cardiacassist.com/research/articles/ASAIO01.pdf>, artificial hearts (see e.g., U.S. Pat. No. 6,346,120 to Yamazaki, et al.), neuromuscular stimulators (see e.g., U.S. Pat. No. 6,163,725 to Peckham, et al.), cochlear implants (see e.g., U.S. Pat. No. 5,344,387 to Lupin, artificial hearing and vision devices (see e.g., U.S. Pat. No. 6,394,947 to Leysieffer (hearing) and U.S. Pat. No. 5,556,423 to Chow, et al. (vision)), deep brain stimulation devices (see e.g., U.S. Pat. No. 6,427,086 to Fischell, et al.), electronic pain blockers, automatic drug delivery (see e.g., U.S. Pat. No. 6,416,493 to Del Giglio), therapeutic alarms/signals (see e.g., U.S. Pat. No. 6,328,699 to Eigler, et al.) and sensor/biotelemetry devices (see e.g., U.S. Pat. No. 6,424,867 to Snell, et al. and U.S. Pat. No. 6,409,674 to Brockway, et al.). As a result, people are experiencing longer and much improved qualities of life. New and more sophisticated bioelectronic devices continue to be developed and it is anticipated that the need for better sources of power will increase, with a growing need for implantable power modules with improved reliability, safety and cost-effectiveness. The present invention results from extensive research and development in the area of implantable electrical power sources, particularly rechargeable batteries and their associated devices.
Numerous electrically powered medical devices have been implanted in recent years. Power to operate these devices has been provided from an external source or, if implanted, a power source has been specifically designed for each particular device.
The need for a standardized power source around which a wide variety of medical devices may be designed, and one which is rechargeable by transcutaneous induction has to date not been met. Moreover, such a power module could be located remotely from a medical device (e.g., an atrial assist pump), minimizing stress on the patient by placing it in a more spacious body cavity (e.g., a subcutaneous pocket created in the abdomen). Such an integrated power source would give significantly increased design flexibility to designers of implantable medical devices. The present invention overcomes the limitations inherent in having to provide external power, external recharging connections, or surgically-replaceable primary batteries for implantable medical devices. Moreover, it overcomes the limitations of other implantable batteries with inductively charged batteries, allowing broad flexibility for design of implantable medical devices. In addition, the present invention overcomes the difficulties associated with precisely locating the implanted secondary charging coil to maximize charging efficiency.
A primary objective of the present invention is to provide an implantable power module (hereinafter “IPM”) containing an energy storage device (e.g., a battery), a PMC, and an MICS for remote communication.
A further objective of the invention is to provide an IPM with one or more homing devices or internal functions for easily locating the device once implanted for possible explant, medical treatment, or recharging purposes.
A further objective of the invention is to provide an IPM incorporating safety devices and design aspects to prevent overheating in the event of a malfunction such as an internal or external short circuit, overcharging, overdischarging, or breach of the battery case.
Yet a further objective of the invention is to provide an IPM that allows inductive recharging of the energy storage device without excessive inductive heating of any portion of the IPM or associated medical devices.
A further objective of the invention is to provide a means for precisely locating a secondary charging coil, or any other implanted device.
The present invention comprises an IPM which can be implanted in a human or animal for extended periods of time, and, contained within a hermetic biocompatible case having a highly reliable external connector (external hermetic plug), a source of electrical power, a control circuit, an inductive recharging coil (in the case of secondary batteries and/or capacitors), a homing device for precisely locating the implanted module, and safety devices and design aspects to protect the patient in which the IPM is implanted. The source of power may be one or more primary or secondary cells (hereinafter, “battery”), a capacitor, a nuclear-heated thermopile or nuclear battery, or combinations of the above. Lithium cells are generally considered the best overall compromise of energy capacity, reliability, safety, and rate capability. However, hybrid devices having properties of both lithium cells and super capacitors may have improved performance depending on the demands of the device it is powering. While the term “battery” is used for convenience herein, its meaning may include any electrical storage or generation device.
The present invention has numerous advantages over prior art. (1) It provides design flexibility for medical device developers who do not need to restrict their designs in order to accommodate a power supply. (2) The invention provides a stand-alone power source that can be readily connected to a medical device or multiple devices with a sealed connection within the body. (3) The invention can be located remotely from the medical device it is powering, allowing implantation of medical devices in confined spaces, connecting to the IPM via power leads run within the body. (4) In its smaller embodiments, the present invention can be injected or laparoscopically inserted, reducing the intrusiveness, trauma and cost of surgical procedures, and reducing recovery time. (5) The invention may be located readily for surgical intervention, replacement, etc. (6) The patient is protected from potentially catastrophic failures of the power source by several active and passive design features. (7) The implanted charging coil, or the IPM itself, can be located with great precision.
The IPM can be designed in several general configurations, primarily dictated by size or capacity.
a is a cross-sectional diagram of a preferred embodiment of the present invention.
b is a cross-sectional diagram of another preferred embodiment of the present invention.
a, 2b, 2c, 2d and 2e are cross sectional diagrams of alternative configurations of the preferred embodiment of the present invention.
a and 3b are diagrams of two configurations of a middle-size (approximately 10-500 mAh) IPM.
Referring to
Preferred Embodiment
a, 2b, 2c and 2d illustrate the general configurations in which the present invention can be manufactured.
The PMC 132 provides functions for managing the safety and operation of the IPM 120. This includes shutdown features such as overcharging, over-discharging, thermal sensory feedback, charge/voltage controls, and a homing function. The homing function (more fully describe below) allows the IPM 120 to be easily located for future intervention.
The biocompatible housing 136 is made of titanium or a titanium alloy 144, ceramic 148, other biocompatible metal alloy, or a combination of metal and ceramic (as illustrated here). Ceramic 148 is the preferred housing material since it has infinite electrical resistance and hence is transparent to a magnetic field, minimizing interference, and facilitating more efficient inductive charging. The external case 136 also incorporates an external connection feature 152 to which one or more devices (not shown) can be connected.
b and 2c illustrate two alternative connector geometries for the device illustrated in
d illustrates the configuration of the IPM 170 more suited for the middle range of approximately 10-500 mAh. This size range IPM generally has all the characteristics of the smaller unit described above with reference to
e illustrates the largest size design configuration, generally applicable to approximately 500 mAh to 20 Ah. This size IPM 190 incorporates all of the attributes of the middle size IPM described above with reference to
a and 3b illustrate middle size (10-500 mAh) IPM configurations in which the secondary inductive charging coil is located with the IPM case (
The PMC 264 also controls the rate of charge from the inductive charging coil 280. Additionally, the PMC 264 incorporates a precise homing function to assist in easily locating the IPM. The PMC may also incorporate a communication means for remotely interrogating the status of the IPM, switching it on or off, programming it or otherwise adjusting its performance, or alerting a remote receiver of a malfunction or abnormal state. Such communications feature will normally take the form of signals carried on the inductive charging pathway (e.g., pulses or modulation of the inductive field) or radio frequency transmissions, but may also be light signals (visible or invisible spectrum; 400 to 700 nm or 0.8 to 2.5-μm ranges), aural, tactile (e.g., piezoelectric device), chemical (e.g., the release of a taste to alert the patient of a malfunction) or a low-level radioactive source. An initiator circuit (not shown) may be included which, when signaled would switch on an RF transmitter (not shown) located at the center of the secondary charging coil 280 to assist in precisely finding its location. A less desirable means for locating the charging coil 280 would be the use of a biocompatible tendril or protrusion (not shown) extending from a known location on the charging coil 280 (e.g., the center) to near the top layer of skin (intercutancously) so that it can be felt by touch or mild palpation. Extending the tendril or protrusion through the skin (transcutaneously) is less preferred due to the increased risk of infection, but may be used where warranted.
The external surface of the case has soft contours to avoid biostress, which is a typical human body reaction to foreign objects with sharp edges.
Additionally, the Protection Circuit communicates with the outside world providing battery status and alarms for unsafe conditions (e.g., low battery, over voltage, excess heat) 320. Based on the monitored parameters, the protection circuit enables or disables charging or discharging of the battery 324 (to the device). If enabled, the device receives current from the battery 328 and/or the primary coil 332. Additional functions may also be included such as primary or back-up control circuitry for the implanted device, biotelemetry, and other diagnostic functions. Optionally, the system may be controlled from outside the patient via an External Control Function (not shown). A receiver may be incorporated into the Protection Circuit, or may be incorporated as a separate or hybrid circuit. However incorporated, the receiver functions to respond to signals from outside the patient to modify the function of the IPM or the implanted medical device.
The specific implementations disclosed above are by way of example and for enabling persons skilled in the art to implement the invention only. We have made every effort to describe all the embodiments we have foreseen. There may be embodiments that are unforeseeable and which are insubstantially different. We have further made every effort to describe the invention, including the best mode of practicing it. Any omission of any variation of the invention disclosed is not intended to dedicate such variation to the public, and all unforeseen, insubstantial variations are intended to be covered by the claims appended hereto. Accordingly, the invention is not to be limited except by the appended claims and legal equivalents.
This application claims priority to provisional application No. 60/402,323 filed Aug. 9, 2002. This application is a continuation-in-part of copending application Ser. No. 10/042,898 filed Jan. 9, 2002 now U.S. Pat. No. 6,586,912 entitled “Method and Apparatus for Amplitude Limiting Battery Temperature Spikes” and copending application Ser. No. 10/014,757 filed Nov. 7, 2001 now U.S. Pat. No. 6,531,847 entitled “Electrochemical Battery Safety Method, Device and System”, each of which is incorporated herein in its entirety by reference, including all disclosures submitted therewith.
Number | Name | Date | Kind |
---|---|---|---|
3794041 | Frei et al. | Feb 1974 | A |
3942535 | Schulman | Mar 1976 | A |
4010760 | Kraska et al. | Mar 1977 | A |
4119103 | Jirak | Oct 1978 | A |
4197850 | Schulman et al. | Apr 1980 | A |
4232679 | Schulman | Nov 1980 | A |
4469104 | Peers-Trevarton | Sep 1984 | A |
5025550 | Zirbes et al. | Jun 1991 | A |
5047044 | Smith et al. | Sep 1991 | A |
5084699 | DeMichele | Jan 1992 | A |
5149603 | Fleming et al. | Sep 1992 | A |
5193540 | Schulman et al. | Mar 1993 | A |
5304915 | Sanpei et al. | Apr 1994 | A |
5314451 | Mulier | May 1994 | A |
5411537 | Munshi et al. | May 1995 | A |
5411538 | Lin | May 1995 | A |
5573551 | Lin et al. | Nov 1996 | A |
5616140 | Prescott | Apr 1997 | A |
5629678 | Gargano et al. | May 1997 | A |
5645960 | Scrosati et al. | Jul 1997 | A |
5702432 | Chen et al. | Dec 1997 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
H1765 | O'Phelan et al. | Dec 1998 | H |
5989245 | Prescott | Nov 1999 | A |
6009350 | Renken | Dec 1999 | A |
6040082 | Haas et al. | Mar 2000 | A |
6087809 | Gan et al. | Jul 2000 | A |
6120502 | Michelson | Sep 2000 | A |
6166518 | Echarri et al. | Dec 2000 | A |
6273904 | Chen et al. | Aug 2001 | B1 |
6278258 | Echarri et al. | Aug 2001 | B1 |
6315721 | Schulman et al. | Nov 2001 | B2 |
6400991 | Kung | Jun 2002 | B1 |
6426628 | Palm et al. | Jul 2002 | B1 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6564807 | Schulman et al. | May 2003 | B1 |
20020098410 | Leysieffer et al. | Jul 2002 | A1 |
Number | Date | Country |
---|---|---|
0 178 769 | Apr 1986 | EP |
0 178 769 | Apr 1986 | EP |
03-263753 | Nov 1991 | JP |
06-114036 | Apr 1994 | JP |
09-327447 | Dec 1997 | JP |
WO 0108578 | Feb 2001 | WO |
WO 0207598 | Jan 2002 | WO |
WO 0241755 | May 2002 | WO |
Number | Date | Country | |
---|---|---|---|
20030085684 A1 | May 2003 | US |
Number | Date | Country | |
---|---|---|---|
60402323 | Aug 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10042898 | Jan 2002 | US |
Child | 10310390 | US | |
Parent | 10014757 | Nov 2001 | US |
Child | 10042898 | US |